Evaluation of polysomnography changes in patients using antidepressants

Year 2023, Volume: 6 Issue: 2, 342 - 346, 27.03.2023

Mehmet Kara , Soner Kılıç

https://doi.org/10.32322/jhsm.1216676

Abstract

Aim: In patients followed up with sleep disorders and receiving antidepressant treatment, the choice of antidepressant should be appropriate to the characteristics of the patient and the drug. The aim of this study is to show the effects of antidepressant drug selection on polysomnography results.
Material and Method: This study was planned retrospectively and was conducted by scanning patient files. Between 01.06.2018 and 01.06.2022, the files of patients who underwent polysomnography in the sleep laboratory of our hospital and were using antidepressants were scanned. Differences between antidepressant groups and polysomnography results were analyzed with IBM SPSS v23.
Results: 103 patients (43 women/60 men) were included in the study. It was determined that 56 of these patients used selective serotonin reuptake inhibitors and 47 of them used serotonin and norepinephrine reuptake inhibitors. Yates correction was used in the comparison of gender according to the groups, and there was no statistically significant difference between the distributions of gender according to the groups (p=0.248). According to the drug groups, the results of the polysomnography examined in the study do not differ according to the groups.
Conclusion: It was shown that the antidepressant groups examined in the study did not differ in terms of affecting the results of polysomnography. Other clinical characteristics of the patient can be taken into account in the selection of antidepressants in these groups.

Keywords

Polysomnography, Antidepressants, Serotonin, Norepinephrine

References

• Gülbay B, Acıcan T. Obstrüktif uyku apne sendromunda medikal tedavi. Turkiye Klinikleri Journal of Pulmonary Medicine Special Topics 2008; 1: 120.
• Berry RB, Gamaldo CE, Harding SM, et al. AASM Scoring Manual Version 2.2 Updates: New Chapters for Scoring Infant Sleep Staging and Home Sleep Apnea Testing. J Clin Sleep Med 2015; 11: 1253-4.
• Lee KA. An overview of sleep and common sleep problems. ANNA J 1997; 24: 614-23, 77; quiz 24-5.
• Goh DY, Galster P, Marcus CL. Sleep architecture and respiratory disturbances in children with obstructive sleep apnea. Am J Respir Crit Care Med 2000; 162: 682-6.
• Iber C, Ancoli-Israel S, Chesson A, Quan SF for The American Academy of Sleep Medicine The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications 2007 Westchester.
• Butkov Nic. Atlas of clinical polysomnography Synapse Media 2010.
• Kayaalp O. Akılcı Tedavi Yönünde Tıbbi Farmakoloji 12. Baskı Ankara: Pelikan Yayınevleri 2009: 770-95.
• Aron H. Depression: the benefits of early and appropriate treatment. Am J Managed Care 2007: S92.
• Saygın M, Özgüner M. Uykunun mikro yapısı ve mimarisi. Uyku Bülteni 2020; 1: 19-29.
• Pressman M. Evaluating sleep stages. In: Primer of polysomnogram interpretation 1st edition January 14, 2002.
• Karadağ M. Polisomnografi. İçinde: Kaya A, Karadag M, Özlü T. Göğüs Hastalıkları Propedötik İstanbul: Aves. 2004: 255-63.
• Morin CM. Benca RM. Nature and treatment of insomnia, in Sleep Disorders Medicine Basic Science, Technical Considerations and Clinical Aspects, 2008 3rd ed. edited by S. Chokroverty, Elsevier/Butterworth, Philadelphia.
• Thomas R, Timothy R. Insomnia: Pathophysiology and implications for treatment, Theoretıcal revıew. Ron Pies Sleep Medicine Reviews 2007; 11: 71–9.
• Banks S, Dinges DF. Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med 2007; 3: 519-28.
• Hutka P, Krivosova M, Muchova Z, et al. Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment. Int J Mol Sci 2021; 22: 1333.
• Monaca C, Boutrel B, Hen R, Hamon M, Adrien J. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: Studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003; 28: 850–6.
• Sallanon M, Buda C, Janin M, et al. Implication of serotonin in sleep mechanisms: induction, facilitation? Neurotransmitters and Neuromodulators. New York: Raven Press 1985 p. 136.
• Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20: 533-59.
• Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59: 1052–60.
• Katerndahl D, Ferrer R. Knowledge about recommended treatment and management of major depressive disorder, panic disorder, and generalized anxiety disorder among family physicians. Prim Care Companion J Clin Psychiatry 2004; 6, 147–51.
• Örsel, S. Depresyonda Tedavi: Genel İlkeler ve Kullanılan Antidepresan İlaçlar. Klinik Psikiyatri 2004; 4: 17–24.
• Köktürk, Oğuz. Uyku kayıtlarının skorlanması. Türk Solunum Araştırma Derneği Solunum 2013; 15: 14-29.